Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Should Life Expectancy Guide Treatment Decisions in Low- and Intermediate-Grade Early Prostate Cancer?

Should Life Expectancy Guide Treatment Decisions in Low- and Intermediate-Grade Early Prostate Cancer?

Prostate cancer treatment is a personal decision. All aspects of the options should be evaluated, and treatment should be chosen together with the patient.

Several options are available for early-stage prostate cancer, including surgery, radiotherapy and close observation. Each has advantages and disadvantages compared with the others. All relevant factors must therefore be assessed to determine the most appropriate approach for an individual patient.

Aggressive approaches such as surgery and radiotherapy can substantially reduce quality of life in early-stage prostate cancer. They may be much riskier when other illnesses are present and can even increase deaths from causes other than cancer. Conservative approaches may therefore be a better option when the risk of death from cancer is low, the risk of death from other causes is high, and life expectancy is short. Conservative treatment aims to prevent progression and control the disease through close observation and drug treatments. Respected guideline organizations, including the American Urological Association and European Association of Urology, recommend conservative rather than aggressive treatment for low- and intermediate-grade early-stage prostate cancer when life expectancy is less than 10 years. Many studies have shown that aggressive treatments do not provide substantial survival benefits in these patients.

However, life expectancy is often overlooked in treatment decisions because data on 10-year survival according to age and accompanying illnesses in men with prostate cancer have been insufficient. Previous studies examined age-related life expectancy, life expectancy according to accompanying illnesses, and treatment choice, but none in the literature considered these two criteria together. A recently published comprehensive study on this issue provides important guidance.

The study included data on approximately 96000 patients aged 66 or older with low- or intermediate-grade early-stage prostate cancer. Patients were scored according to the number and severity of accompanying illnesses, with higher scores indicating more numerous and severe conditions, and grouped by age. Life expectancy was less than 10 years among patients aged 66-69 with scores of 2 or higher, those aged 70-74 with scores of 1 or higher, and all patients aged 75 or older. Nevertheless, among patients with life expectancy below 10 years, aggressive treatments were given, contrary to recommendations, to 68% of those aged 66-69, 69% of those aged 70-74, 57% of those aged 75-79, and 24% of those aged 80 or older.

In conclusion, prostate cancer treatment is a personal decision. All aspects of the options should be evaluated, and treatment should be chosen together with the patient. Life expectancy should be among the decision criteria. Aggressive treatments are not recommended for low- and intermediate-grade early-stage prostate cancer when life expectancy is less than 10 years. This study provides important guidance for estimating life expectancy. We hope it will encourage physicians to give this criterion greater consideration when choosing appropriate treatment.

Sources

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Should Life Expectancy Guide Treatment Decisions in Low- and Intermediate-Grade Early Prostate Cancer?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy